Does Vitamin D Prevent Recurring BV?Two Trials Asked Different Questions

If BV keeps returning after treatment, a blood test showing low vitamin D can seem to offer an explanation and a fix. But correcting a nutrient level and preventing another episode are separate outcomes. A trial can achieve the first without achieving the second.

The U.S. trial raised blood levels without reducing recurrence

Published in 2014, the trial¹ analyzed 118 women with symptomatic BV at an Ohio sexual-health clinic. All received a seven-day metronidazole course. The vitamin D group received nine 50,000-IU doses over 24 weeks; controls received matching placebo.¹

At the final visit, median vitamin D blood levels were 30.5 ng/mL with supplementation and 17.8 ng/mL with placebo. However, the recurrence hazard ratio was 1.11, with a 95% confidence interval of 0.68 to 1.81. It did not show reduced recurrence.¹

The interval includes 1, the no-difference value. The study therefore cannot supply a dependable percentage reduction for a supplement advertisement.

Only 78 women returned at week 24. There was also no test confirming clearance immediately after antibiotic treatment, so later positive findings could include persistent BV and episodes that returned after clearance. These limitations reduce certainty; they do not turn the result into a benefit.¹

The positive trial tested symptom-free BV

An Iranian study published in 2015 randomized 211 women and analyzed 208. Participants were aged 18 to 35, had BV on a vaginal laboratory score, and reported no odor or abnormal discharge. The study defined vitamin D deficiency as a blood level below 75 nmol/L.²

Participants received 2,000 IU daily for 15 weeks or placebo drops. BV clearance on the laboratory score occurred in 63.5% of the vitamin D group and 19.2% of controls. The study excluded symptomatic BV because those women required antibiotics. It did not establish whether clearance lasted after supplementation ended.²

That distinction matters if your question is, “Will another supplement keep the odor and discharge from returning after treatment?” A trial of a laboratory finding in women without symptoms does not answer that question directly.

Why comparing only the headlines misleads

The studies differed in their starting population, supplement schedule and intended outcome. One added intermittent supplementation to antibiotic treatment for symptomatic BV and followed subsequent positive tests. The other used daily supplementation in selected women without symptoms and measured clearance at the end of treatment.¹²

A favorable clearance result cannot be substituted for a recurrence result. Nor can the difference between the papers identify a better dose: the trials did not randomly compare their two schedules in otherwise comparable patients.

When reading a claim about vitamin D and BV, look for three particulars:

• Starting condition: symptoms, a laboratory result, or both.
• Treatment context: supplement alone or alongside an antibiotic.
• Outcome: blood vitamin level, BV clearance or a later recurrence.

“Improved vitamin D” tells you about the nutrient measurement. The BV outcome still needs to be reported.

What the CDC recommends about recurrence

The CDC’s³ currently posted BV treatment guideline does not recommend high-dose vitamin D to prevent recurrence. It advises returning for evaluation when symptoms recur and describes prescription suppressive approaches for multiple recurrences.³

Those approaches require a clinician’s plan. Bring dates of previous episodes, which treatments you completed, how long symptoms stayed away and any test results. Our article on BV that keeps returning examines that broader treatment discussion.

If you are pregnant and have symptoms, seek assessment rather than relying on supplements: the CDC³ recommends treating symptomatic BV during pregnancy. Neither trial above provides a pregnancy-treatment plan.³

A deficiency still deserves its own discussion

The vitamin D findings are not a reason to abandon a supplement prescribed for a diagnosed deficiency or another indication. They are a reason to ask what outcome the prescription is intended to achieve.

The NIH Office of Dietary Supplements⁴ gives 4,000 IU daily as the adult upper limit from food, drinks and supplements combined. It notes that clinicians may prescribe higher doses temporarily to treat deficiency. The upper limit is not a target dose, and an intermittent 50,000-IU research capsule should not be copied into a daily routine.⁴

Excessive supplemental vitamin D can cause harm, including kidney stones and, at extreme levels, kidney failure. Review the total from your multivitamin and any separate supplement with your clinician or pharmacist before increasing it.⁴

Chapter 7, “Here We Go Again,” in Down There, Decoded covers recurrent BV, confirmation of the cause and prescription options. Use that discussion to prepare a recurrence plan while keeping the vitamin D question tied to the reason it was prescribed.